Pfizer Inc. (NYSE:PFE) Shares Purchased by Caldwell Sutter Capital Inc.

Caldwell Sutter Capital Inc. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 2.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 73,621 shares of the biopharmaceutical company’s stock after acquiring an additional 1,674 shares during the period. Pfizer accounts for about 1.0% of Caldwell Sutter Capital Inc.’s investment portfolio, making the stock its 17th largest position. Caldwell Sutter Capital Inc.’s holdings in Pfizer were worth $2,043,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 8.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock valued at $2,985,783,000 after purchasing an additional 8,473,686 shares in the last quarter. Morgan Stanley lifted its holdings in Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock valued at $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Norges Bank purchased a new position in Pfizer in the 4th quarter valued at about $2,129,927,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 13.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PFE shares. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, June 26th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $35.54.

Pfizer Trading Down 0.5 %

PFE traded down $0.13 during trading on Wednesday, reaching $27.70. The company had a trading volume of 15,170,974 shares, compared to its average volume of 40,441,543. The firm’s 50-day simple moving average is $27.96 and its 200 day simple moving average is $27.71. The company has a market cap of $156.96 billion, a price-to-earnings ratio of -462.33, a PEG ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.06%. Pfizer’s payout ratio is presently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.